Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback